PIHN Announces Procannas' Cannabinoid Transdermal Product Development
07 4월 2014 - 8:15PM
Marketwired
PIHN Announces Procannas' Cannabinoid Transdermal Product
Development
PLANO, TX--(Marketwired - Apr 7, 2014) - Polaris International
Holdings, Inc. (OTC Pink: PIHN) (PINKSHEETS: PIHN) is excited to
announce its medical division, ProCannas, has begun development of
a unique and proprietary transdermal patch capable of delivering
cannabinoids directly through the skin. This hallmark solution is
intended to address a significant, unmet need for individuals
requiring long-term, time released delivery. The Company
believes, subject to testing and trials to be initiated by our
participating physicians, that the patch may able to deliver
cannabinoids for up to 48 hours. The Company further expects
that this mechanism of delivery could revolutionize the way
cannabinoids are introduced into the blood stream minimizing the
negative effects on lungs and other organs commonly seen in other
delivery methods. The Company expects to be ready to begin trials
in 90 days.
The Company intends to target a broad range of specialties with
this novel product, including but not limited to sports medicine,
pain management, neurology, and osteopathic medicine.
"Transdermal delivery of Cannabinoids has a global reach because
diseases such as osteoporosis which affects about 52 million
Americans and causes more than 8.9 million fractures worldwide
annually, resulting in an osteoporotic fracture every 3 seconds,
will greatly benefit from this method of delivery. It will
ensure long term absorption on a continual basis in order to
alleviate the targeted symptoms. Constant delivery of
cannabinoids transdermally will also help to reduce pain and
swelling in other medical conditions," states Medical Director, Dr.
Vasthi Alvarez Avila.
ABOUT THE COMPANY
ProCannas core business focuses on the manufacture and
distribution of new, pharmaceutical grade cannabinoid based
products for medicinal use. Due to the concentrated strength
and unique mix of ingredients integrated within our products, they
are intended to be available to patients only through licensed
participating physicians. Due to recent changes in the law
regarding the medical use of marijuana, coupled with studies and a
strong body of evidence highlighting that THC is not the
significant component for medicinal use, doors are opening for
innovation. Laws are expected to become even more favorable
for companies like ProCannas.
Safe Harbor Statement:
This news release includes
forward-looking statements pertaining to future anticipated
projected plans, performance and developments, intended to qualify
for the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Any statements on this
news release that are not statements of historical fact should be
considered forward-looking statements. These forward-looking
statements generally can be identified by phrases such as
"believes," "expects," "anticipates," "foresees," "forecasts,"
"estimates," "intends," or other words or phrases of similar
import. Similarly, statements in this news release that describe
the Company's business strategy, outlook, objectives, plans,
intentions or goals also are forward-looking statements. All such
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially
from those in forward-looking statements.
Investor Inquiries: Polaris International Holdings, Inc.
WWW.Procannas.net Info@Procannas.net
Polaris (CE) (USOTC:PIHN)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Polaris (CE) (USOTC:PIHN)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024